The REACT-2 trial compared the effectiveness of two treatment algorithms, enhanced care or step-care, to reduce the risk of Crohn’s disease related complications at 2 years. In this touchIMMUNOLOGY interview, we speak with Dr Vipul Jairath (Western University, University Hospital, London, ON, Canada) to discuss the REACT-2 trial and future studies.
The abstract entitled ‘A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2’ (Abstract no: OP110) was presented at UEG Week, October 8 – 11, 2022.
Question:
- What were the aims, design, treatment algorithms and eligibility criteria of the REACT-2 study? (0:21)
- What were the primary and secondary outcome measures, and how well were they achieved in the different treatment arms? (1:21)
- Could you tell us about the post-hoc analysis and its findings? (2:12)
- What were the conclusions of the investigators? (2:36)
- What future studies are planned? (3:07)
Disclosures: Vipul Jairath is a consultant for AbbVie, Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), Amgen, Applied Strategic, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, BioJamp. Celgene/BMS, Celltrion, Eli Lilly, Ferring, F. Hoffman-La Roche Ltd, Flagship Pioneering, Fresenius Kabi, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Organon (Merck), Landos BioPharma, Mylan, Pandion, Pendopharm, Pfizer, Protagonist Therapeutics, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva, Topivert, Ventyx Biosciences, Vividion Therapeutics. He is also a speaker’s bureau participant with Abbvie, Ferring, Galapagos, Janssen, Pfizer, Takeda.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of UEG Week 2022
Access more content on Gastroenterology here
